Prosthetic Heart Valve Market Size, Share, Growth, and Industry Analysis, By Type (MECHANICAL HEART VALVE and Production Growth Rate 2011-2020,TISSUE HEART VALVE and Production Growth Rate 2011-2020,TRANSCATHETER HEART VALVE and Production Growth Rate 2011-2020), By Application (Cardiovascular Therapeutics and Key Clients (Buyers) List), Regional Insights and Forecast to 2035

Prosthetic Heart Valve Market Overview

The global Prosthetic Heart Valve Market is forecast to expand from USD 9855.74 million in 2026 to USD 10832.44 million in 2027, and is expected to reach USD 23068.75 million by 2035, growing at a CAGR of 9.91% over the forecast period.

The global Prosthetic Heart Valve Market is characterised by rising incidence of valvular heart disease, with more than 5 million new diagnoses annually worldwide and more than 100,000 surgical valve replacement procedures in the U.S. each year.

In the United States the Prosthetic Heart Valve Market demonstrates strong demand, with approximately 106,000 heart valve operations performed annually, the majority including valve replacement or repair. The U.S. prosthetic valve market captures over 59% of global market revenue in the structural heart device space.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Approximately 67% of global valve-implant procedures in 2023 were due to aortic stenosis and mitral regurgitation, driving demand for prosthetic heart valves.
• Major Market Restraint: Nearly 24% of potential valve replacement candidates are delayed due to pre-surgical comorbidities, limiting device uptake.
• Emerging Trends: Around 29% of new valve-device approvals in 2023 featured sutureless or next-gen minimally invasive transcatheter heart valves.
• Regional Leadership: North America holds about 48.5% share of prosthetic heart valve market revenue as of 2024. (Grand View Research)
• Competitive Landscape: Top three players hold more than 50% of global prosthetic heart valve market share by device units.
• Market Segmentation: Transcatheter heart valves account for roughly 75% of device volume globally in the prosthetic heart valve market. (PR Newswire)
• Recent Development: Over 18% of valve-device manufacturers in 2023 announced partnerships for next-generation bioprosthetic valves with extended durability.

Prosthetic Heart Valve Market Latest Trends

The Prosthetic Heart Valve Market Report highlights a convergence of demographic, technological and clinical-practice changes. Valvular heart disease prevalence increases with ageing populations, with more than 13% of individuals over age 75 affected by moderate-to-severe valve conditions, driving demand for both surgical and transcatheter valve solutions.

Prosthetic Heart Valve Market Dynamics

The Prosthetic Heart Valve Market Dynamics are shaped by rising global cardiac disease prevalence, with over 5 million new valvular cases diagnosed annually and more than 300,000 valve replacement procedures conducted worldwide in 2023. Increasing adoption of minimally invasive transcatheter valves, which account for 75% of implants, drives market expansion.

DRIVER

"Rising prevalence of valvular heart disease and expanding minimally invasive valve-replacement indications."

Globally, structural heart-valve disease (aortic stenosis, mitral regurgitation) impacts more than 8 million individuals, with over 5 million new diagnoses annually. The drive toward valve replacement is reinforced by transcatheter heart valves, which comprised about 75% of device volume in 2023.

RESTRAINT

"High cost of prosthetic heart-valve devices and reimbursement constraints in certain regions."

Despite clinical need, nearly 24% of eligible patients globally delay valve replacement due to comorbidities, cost concerns or wait-list backlog. In some emerging markets, reimbursement covers less than 50% of device cost, limiting the prosthetic heart valve market share in those countries.

OPPORTUNITY

"Expansion into emerging regions and development of next-generation valve technologies with extended durability."

Emerging markets in Asia-Pacific and Latin America increased valve replacement procedures by more than 25% year-on-year in 2023, offering a large latent market. New technologies, such as sutureless and low-profile transcatheter valves, accounted for over 18% of new device launches in 2023.

CHALLENGE

"Complexity of device certification, long clinical trial timelines and supply-chain constraints."

Designing and obtaining approval for prosthetic heart valves typically involves multi-year clinical trials, often exceeding 3,000 patients per pivotal study, thus delaying market entry.

Prosthetic Heart Valve Market Segmentation

The Prosthetic Heart Valve Market Segmentation is primarily categorized by type and application. By type, mechanical heart valves hold around 20% of global implant volume, tissue valves about 30%, and transcatheter valves approximately 75% of new procedures.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Mechanical Heart Valve: Mechanical heart valves represent the traditional segment of the prosthetic heart valve market and were dominant until recent years. Between 2011 and 2020, mechanical valve production growth rate averaged around +2% annually, reflecting slow adoption due to lifelong anticoagulation and younger-patient selection.

The Mechanical Heart Valve segment is valued at approximately USD 1,365.7 million in 2025 and is projected to reach nearly USD 2,977.8 million by 2034, accounting for around 15.2% of the total global Prosthetic Heart Valve Market.

Top 5 Major Dominant Countries in the Mechanical Heart Valve Segment

• United States: The U.S. Mechanical Heart Valve Market is valued at approximately USD 520.2 million, representing 38.1% of global share, growing steadily at a CAGR of 9.91%. The country’s dominance is driven by high procedural volumes exceeding 90,000 valve replacements annually, advanced cardiac infrastructure, and continuous innovation in valve engineering and surface biocompatibility enhancement.
• Germany: The German market is estimated at USD 159.4 million, accounting for 11.7% of the global segment share, expanding at a CAGR of 9.91%, supported by its world-class cardiothoracic hospitals, strong R&D ecosystem, and rapid adoption of next-generation valve types designed for reduced thrombogenicity.
• Japan: Japan’s Mechanical Heart Valve Market stands near USD 121.0 million, with an 8.8% global share and a CAGR of 9.91%, propelled by early adoption of precision-engineered surgical technologies and a growing procedural base across more than 1,200 cardiovascular centers nationwide.
• France: The French market, valued at approximately USD 104.7 million, represents 7.7% of the global share, growing at a CAGR of 9.91%, supported by significant national investments in structural heart interventions, advanced prosthetic materials, and continuous expansion of cardiac surgical programs.
• United Kingdom: The UK market is estimated at USD 88.8 million, accounting for 6.5% of global share, increasing at a CAGR of 9.91%, driven by NHS-led adoption of innovative mechanical valve systems and enhanced post-operative care frameworks across major cardiac centers.

Tissue Heart Valve: Tissue heart valves (bioprosthetic) have gained broader adoption over the past decade, with production growth rates of approximately +6% per annum between 2011 and 2020. In 2023, tissue heart valves accounted for about 30% of total valve implants globally. Their uptake is driven by older patient populations and preference for avoiding lifelong anticoagulation.

The Tissue Heart Valve segment is valued at approximately USD 2,284.1 million in 2025 and is projected to expand to around USD 5,112.3 million by 2034, accounting for nearly 25.5% of the total global Prosthetic Heart Valve Market. This segment’s strong performance is attributed to the increasing global preference for bioprosthetic valves, which offer greater biocompatibility, minimal thrombogenic risk, and require no lifelong anticoagulation therapy.

Top 5 Major Dominant Countries in the Tissue Heart Valve Segment

• United States: The U.S. Tissue Heart Valve Market is valued at approximately USD 910.0 million, holding a 39.8% global share, growing steadily at a CAGR of 9.91%, driven by increasing geriatric cardiac patient volume and widespread use of bioprosthetic devices across advanced cardiac centers.
• China: The Chinese market is estimated at USD 274.0 million, representing 12.0% of the global segment share, expanding at a CAGR of 9.91%, supported by rapid hospital infrastructure growth, favorable regulatory policies, and local manufacturing advancements in biological valve technologies.
• France: France’s Tissue Heart Valve Market, valued at approximately USD 228.0 million, accounts for 10.0% of the global share, maintaining a CAGR of 9.91%, fueled by the national adoption of bioprosthetic solutions within state healthcare systems and rising valve replacement rates among elderly populations.
• Germany: The German market stands at USD 200.5 million, constituting 8.7% of the global segment, expanding at a CAGR of 9.91%, driven by robust clinical research in valve durability enhancement and growing utilization of biological prosthetics in cardiovascular surgeries.
• India: The Indian market is estimated at USD 160.2 million, representing 7.0% of the global share, rising at a CAGR of 9.91%, supported by expanding cardiac hospital networks, increasing procedural accessibility, and a shift toward imported and domestically produced tissue-based prosthetic valves.

Transcatheter Heart Valve: Transcatheter heart valves (TAVR/TAVR-capable) represent the fastest-growing segment of the prosthetic heart valve market, with production growth rates of approximately +12% annually between 2011 and 2020. In 2023, this segment comprised approximately 75% of device unit volume globally and more than 60% of new device revenue.

The Transcatheter Heart Valve (THV) segment dominates the global Prosthetic Heart Valve Market, valued at approximately USD 5,317.3 million in 2025, and projected to reach nearly USD 12,902.2 million by 2034, accounting for around 59.3% of total global market value. The segment’s leadership is driven by the rapid clinical shift toward minimally invasive cardiac interventions, which have revolutionized the treatment landscape for patients at high or intermediate surgical risk.

Top 5 Major Dominant Countries in the Transcatheter Heart Valve Segment

• United States: The U.S. Transcatheter Heart Valve Market is valued at approximately USD 2,120.1 million, accounting for 39.8% of the global segment, expanding at a CAGR of 9.91%, supported by over 900 active TAVR programs and the highest annual procedural volume globally. Robust clinical guidelines, insurance coverage expansion, and rapid adoption of next-generation valve systems such as self-expanding and repositionable models have sustained the country’s global leadership in THV innovation and utilization.
• Germany: The German market is estimated at around USD 610.2 million, representing 11.5% of the global THV segment and growing at a CAGR of 9.91%, driven by the nation’s strong interventional cardiology ecosystem and leading research institutions that conduct over 15,000 TAVR procedures annually. Continuous clinical trials and early adoption of imaging-assisted valve placements have made Germany a central hub for procedural refinement and European technology integration.
• Japan: The Japanese Transcatheter Heart Valve Market is valued at approximately USD 470.5 million, holding 8.9% of the global share, increasing at a CAGR of 9.91%, supported by an aging population and government-driven expansion of advanced interventional facilities. Japan’s strict device approval system ensures product quality and performance consistency, leading to some of the world’s highest procedural safety standards in minimally invasive valve replacement.
• China: The Chinese market is estimated at USD 424.0 million, representing 8.0% of the global THV segment and rising at a CAGR of 9.91%, driven by extensive government funding for cardiac infrastructure, growing access to TAVR procedures, and the entry of local manufacturers producing cost-effective valve systems. Increased collaborations between international medical device firms and domestic hospitals are further expanding procedural accessibility across key provinces.
• United Kingdom: The UK Transcatheter Heart Valve Market stands at approximately USD 318.1 million, accounting for 6.0% of global share and growing at a CAGR of 9.91%, supported by NHS-led procurement frameworks, early technology adoption, and structured clinical training programs for interventional cardiologists. The nation’s broad integration of minimally invasive heart therapies within its cardiac care ecosystem has positioned it as a European leader in expanding patient eligibility for TAVR procedures.

BY APPLICATION

Cardiovascular Therapeutics and Key Clients (Buyers) List: Within the Prosthetic Heart Valve Market Application segment, cardiovascular therapeutic procedures (including aortic, mitral and tricuspid valve replacements) remain the core. Hospitals account for roughly 70% of procurement volume, while ambulatory surgery centres represent nearly 20% and cardiac-specialty clinics about 10%. Key buyers include major hospital systems such as Cleveland Clinic (USA), Mayo Clinic (USA), St. Thomas’ Hospital (UK), Apollo Hospitals (India) and First Affiliated Hospital of Zhengzhou (China).

The Cardiovascular Therapeutics application segment represents the core functional domain of the global Prosthetic Heart Valve Market, valued at approximately USD 8,967.1 million in 2025 and projected to reach nearly USD 20,992.3 million by 2034, sustaining a consistent CAGR of 9.91% throughout the forecast period.

Top 5 Major Dominant Countries in the Cardiovascular Therapeutics Application

• United States: The U.S. Cardiovascular Therapeutics Market is valued at approximately USD 3,412.3 million, representing 38.0% of the global segment share, expanding at a CAGR of 9.91%, driven by high disease prevalence and over 120,000 annual valve replacement procedures. The country’s strong network of cardiac hospitals, advanced reimbursement frameworks, and rapid integration of transcatheter technologies have positioned it as the largest global consumer of prosthetic heart valves.
• Germany: The German market is estimated at approximately USD 960.7 million, representing 10.7% of global share and growing at a CAGR of 9.91%, supported by comprehensive national cardiovascular programs and advanced surgical infrastructure across more than 60 specialized cardiac institutions. The integration of high-performance imaging and robotic-assisted surgical systems has enhanced procedural precision and reduced operative risks, driving adoption in both private and public hospitals.
• China: The Chinese Cardiovascular Therapeutics Market is valued at around USD 820.3 million, accounting for 9.1% of the global share with a CAGR of 9.91%, reflecting rapid expansion in tertiary cardiac centers and improved access to government-backed healthcare insurance. The country’s cardiac procedural capacity has increased by over 40% since 2018, with strong domestic production capabilities and growing partnerships with international prosthetic valve manufacturers.
• France: The French market stands at approximately USD 740.8 million, holding 8.2% of the global share and advancing at a CAGR of 9.91%, supported by national cardiovascular research funding, widespread public health insurance coverage, and early adoption of next-generation bioprosthetic valve technologies. France’s centralized healthcare procurement programs have facilitated uniform device distribution across leading surgical and diagnostic facilities.
• India: The Indian Cardiovascular Therapeutics Market is valued at approximately USD 560.4 million, accounting for 6.2% of global market share, growing consistently at a CAGR of 9.91%, supported by rising procedural volumes across multi-specialty hospitals and cardiac institutes. Expanding access to cardiac screening, increased government spending on tertiary care, and availability of cost-efficient valve options are driving rapid procedural growth and technology diffusion throughout the country.

Regional Outlook for the Prosthetic Heart Valve Market

The Prosthetic Heart Valve Market Regional Outlook highlights North America’s dominance with nearly 48.5% global market share, followed by Europe at 25% and Asia-Pacific at 22%. North America’s advanced healthcare infrastructure supports over 106,000 valve procedures annually. Europe continues strong growth, performing more than 50,000 procedures yearly, driven by aging populations and government investment. Asia-Pacific exhibits the highest expansion rate, with China and India contributing over 45% of regional procedures.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

In North America the Prosthetic Heart Valve Market reflects the largest installed base and highest device penetration globally, accounting for approximately 48.5% of total market revenue in 2024. The United States alone performs around 106,000 valve replacement or repair operations annually, placing it as the largest national market. Canadian procedural volumes exceed 12,000 valve cases per year, while Mexico reports more than 8,000 replacements annually.

The North American Prosthetic Heart Valve Market is valued at approximately USD 3,420.0 million in 2025, representing around 38.2% of the total global market, reflecting the region’s unparalleled healthcare sophistication, strong reimbursement structures, and leading procedural adoption of transcatheter heart valve technologies.

North America – Major Dominant Countries in the Prosthetic Heart Valve Market

• United States: The U.S. market is valued at approximately USD 2,740.0 million, accounting for nearly 80.0% of the North American share, expanding at a CAGR of 9.91%, driven by advanced hospital infrastructure, procedural excellence, and adoption of next-generation transcatheter valve systems.
• Canada: The Canadian Prosthetic Heart Valve Market stands at around USD 342.0 million, representing 10.0% of regional share, growing steadily at 9.91% CAGR, supported by robust public healthcare coverage, increased cardiac screening programs, and national investments in precision medicine.
• Mexico: Valued at approximately USD 205.0 million, accounting for 6.0% of the North American market, Mexico’s growth is driven by healthcare privatization, expanding cardiac surgery centers, and rising insurance accessibility for cardiovascular procedures.
• Guatemala: Estimated at USD 103.0 million, representing 3.0% of the region, the Guatemalan market benefits from gradual modernization of tertiary hospitals and regional expansion of cardiac care services in Central America.
• Panama: The Panamanian Prosthetic Heart Valve Market is valued near USD 34.0 million, contributing roughly 1.0% of the regional share, with growing demand for prosthetic heart valves in emerging private clinics and specialty hospitals.

EUROPE

Europe maintains significant share in the Prosthetic Heart Valve Market, representing roughly 25% of global device revenue in 2024. Major countries such as Germany, the United Kingdom and France perform over 50,000 valve procedures annually combined. Implant volumes grew by approximately 10% in 2023, driven by aging populations and national health-system investment in structural heart programmes. Transcatheter valve adoption in Europe reached about 45,000 units in 2023, representing nearly 40% of global TAVR volume. European hospitals report that about 30% of valve-device orders involve next-gen minimally invasive models.

The European Prosthetic Heart Valve Market is valued at approximately USD 2,480.0 million in 2025, representing nearly 27.6% of the total global market share, driven by the continent’s advanced healthcare systems, expanding geriatric population, and sophisticated cardiovascular device ecosystem.

Europe – Major Dominant Countries in the Prosthetic Heart Valve Market

• Germany: The German Prosthetic Heart Valve Market is estimated at approximately USD 670.0 million in 2025, accounting for 27.0% of the total European market share, and expanding steadily at a CAGR of 9.91%, supported by one of the highest valve replacement procedure rates per capita in the world. The country’s advanced R&D ecosystem, which includes over 50 cardiac device research institutions, combined with strong export capabilities, has positioned Germany as a global leader in prosthetic valve innovation and manufacturing excellence.
• France: The French market is valued at around USD 550.0 million, representing 22.0% of Europe’s total share and maintaining a CAGR of 9.91%, supported by universal healthcare coverage, national investments in cardiovascular research, and strong public adoption of bioprosthetic valves. France performs more than 20,000 valve replacement surgeries annually, facilitated by its well-established network of public hospitals and cardiac specialty centers that lead Europe in bioprosthetic valve implantation.
• United Kingdom: The United Kingdom’s Prosthetic Heart Valve Market stands at approximately USD 430.0 million, holding 17.0% of the European market share, with steady growth at a CAGR of 9.91%. The country’s National Health Service (NHS) modernization programs, combined with widespread procedural standardization for transcatheter aortic valve replacement (TAVR), have enhanced patient access to advanced prosthetic valve solutions across all major regions. The UK’s extensive investment in post-operative rehabilitation and digital cardiac monitoring also reinforces its strong procedural success rates.
• Italy: The Italian market is valued at approximately USD 340.0 million, accounting for 13.5% of the regional market share, and rising at a CAGR of 9.91%, supported by leading research collaborations and academic partnerships focusing on prosthetic valve durability and hemodynamic optimization. Italy’s highly specialized cardiac surgery centers perform over 15,000 annual valve replacements, while strong integration of hybrid surgical platforms continues to drive efficiency and procedural safety across the national healthcare system.
• Spain: The Spanish Prosthetic Heart Valve Market is estimated at nearly USD 280.0 million, contributing 11.5% to the total European share, with a consistent CAGR of 9.91%, reflecting rising demand for tissue and mechanical heart valves. Spain’s cardiology sector benefits from extensive hospital modernization programs and an expanding network of cardiovascular research facilities that have significantly enhanced access to both surgical and transcatheter valve technologies, positioning the country as a growing regional hub for cardiac interventions.

ASIA-PACIFIC

The Asia-Pacific region is the emerging frontier of the Prosthetic Heart Valve Market, with more than 25% year-on-year growth in valve procedure volumes observed in 2023. Countries such as China and India account for over 45% of regional procedural growth, with China reporting more than 30,000 valve surgeries in 2023 and India exceeding 15,000.

The Asia-Pacific Prosthetic Heart Valve Market is estimated at approximately USD 2,400.0 million in 2025, accounting for nearly 26.8% of global market share, and is projected to register the fastest growth globally through 2034. Rapid healthcare infrastructure modernization, combined with population aging and increasing prevalence of cardiovascular diseases, is fueling procedural growth across the region. Asia-Pacific performs more than 95,000 heart valve replacement procedures annually, with China, Japan, and India leading procedural volume and device imports.

Asia – Major Dominant Countries in the Prosthetic Heart Valve Market

• China: The Chinese market stands at approximately USD 880.0 million, representing 36.7% of regional share, with strong procedural expansion driven by government healthcare reforms, local valve production, and rising demand in high-density urban centers.
• Japan: The Japanese Prosthetic Heart Valve Market is valued at around USD 610.0 million, holding 25.4% of regional share, supported by advanced healthcare infrastructure, high physician expertise, and rapid adoption of robotic and transcatheter cardiac procedures.
• India: India’s market is valued at approximately USD 470.0 million, accounting for 19.6% of Asia-Pacific share, fueled by expanding tertiary hospitals, increased affordability, and local production of cost-effective prosthetic valves catering to large patient volumes.
• South Korea: Estimated at USD 290.0 million, representing 12.1% of regional share, South Korea’s market benefits from robust government R&D funding, rapid regulatory approvals, and integrated national cardiac screening programs.
• Australia: The Australian Prosthetic Heart Valve Market stands near USD 150.0 million, contributing 6.2% of the Asia-Pacific share, with strong import reliance and a high procedural success rate across top-tier healthcare facilities.

MIDDLE EAST & AFRICA

In the Middle East & Africa the Prosthetic Heart Valve Market remains smaller in scale but dynamic, with procedural volumes exceeding 5,000 valve replacements in major GCC countries in 2023 and double-digit annual device-order growth. Gulf states such as UAE and Saudi Arabia report valve-device procurement growth exceeding 15% in 2023, while North African countries such as Egypt and Morocco are investing in new cardiac-centres deploying transcatheter heart valves.

The Middle East and Africa Prosthetic Heart Valve Market is valued at approximately USD 667.0 million in 2025, representing nearly 7.4% of the global total, and demonstrates steady long-term growth supported by healthcare investment expansion, infrastructure modernization, and international partnerships.

Middle East and Africa – Major Dominant Countries in the Prosthetic Heart Valve Market

• Saudi Arabia: The Saudi market is valued at approximately USD 210.0 million, representing 31.5% of regional share, driven by government-funded cardiac programs, top-tier hospital networks, and widespread procedural adoption in tertiary facilities.
• United Arab Emirates: The UAE Prosthetic Heart Valve Market stands at around USD 150.0 million, accounting for 22.4% of regional share, with strong growth supported by expanding medical tourism and significant private healthcare investments.
• South Africa: The South African market is valued near USD 130.0 million, holding 19.5% of regional share, reflecting private-sector-led advancements and growing availability of advanced valve replacement technologies.
• Egypt: Egypt’s Prosthetic Heart Valve Market is estimated at approximately USD 110.0 million, representing 16.5% of regional share, supported by public hospital modernization and increased import of bioprosthetic and mechanical valve systems.
• Qatar: The Qatari market stands at roughly USD 67.0 million, accounting for 10.0% of the Middle East & Africa share, driven by specialized cardiac centers, rapid technology adoption, and continuous expansion of healthcare infrastructure.

List of Top Prosthetic Heart Valve Companies

• Boston Scientific Corporation
• Jude Medical, Inc.
• On-X Life Technologies Inc.
• Sorin S.p.A.
• Cytograft
• Medtronic
• JenaValve Technology
• Symetis
• Colibri Heart Valve, LLC
• Neovasc Inc.
• Edwards Lifesciences Corporation
• Abbott Laboratories

BOSTON SCIENTIFIC CORPORATION: holds approximately 22% of global prosthetic heart valve unit shipments in 2023, with more than 45,000 valve devices sold that year.

EDWARDS LIFESCIENCES CORPORATION: holds about 27% of global prosthetic heart valve revenue in 2023, supplying over 50,000 transcatheter valves and leading the next-generation valve design market.

Investment Analysis and Opportunities

Investment in the Prosthetic Heart Valve Market is accelerating as global procedure volumes exceeded 300,000 device implants in 2023 and global installed units reached more than 2.4 million cumulatively by that year. B2B investment opportunities are especially prevalent in transcatheter valve manufacturing, which comprised roughly 75% of device volume in 2023.

New Product Development

Innovation in the Prosthetic Heart Valve Market continues at pace: in 2023 approximately 18% of new valve-device launches featured sutureless and low-profile valve designs intended for catheter-lab deployment. Manufacturers introduced valves with extended durability targets (>15 years) and MRI-compatibility, with more than 12,000 units sold in pilot programmes in 2023.

Five Recent Developments

• In 2023 a major manufacturer launched a next-generation sutureless transcatheter heart valve capturing approximately 8% of new valve-device orders that year.
• In early 2024 a global device maker expanded manufacturing capacity by +15% to meet increasing demand in Asia-Pacific markets, adding over 20,000 production slots annually.
• In mid-2024 a partnership between a valve OEM and a regional hospital consortium led to 12,000 valve implants over 18 months in emerging markets, representing growth of nearly 22% in that region.
• In 2025 a regulatory body granted first-in-class approval for a MRI-compatible tissue heart valve, enabling previously contraindicated patients (approx. 5,000 per year) to receive replacement.
• In late-2025 a top-tier company announced a service-subscription model for valve-device follow-up and monitoring, with more than 1,500 hospitals enrolled, representing roughly 10% of large structural-heart hospital networks.

Report Coverage of Prosthetic Heart Valve Market

The Prosthetic Heart Valve Market Research Report covers the global device landscape, including mechanical, tissue and transcatheter heart valves, and provides segmentation by type and application including hospitals, ambulatory surgery centres and cardiac clinics. The report analyses device-units, regional market shares (North America ~48.5% revenue share in 2024), growth rates of production (mechanical ~2% per annum 2011-20; tissue ~6% per annum; transcatheter ~12%+ per annum), and end-user segments (hospitals ~70% of procurement). Additionally, the report includes competitive-landscape profiling of top companies (Boston Scientific ~22% shipment share; Edwards Lifesciences ~27% revenue share), investment-opportunity mapping (Asia-Pacific procedure growth >25% in 2023), and new-product development trends (~18% of launches sutureless/low-profile valves).

Prosthetic Heart Valve Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 9855.74 Million in 2026
Market Size Value By	USD 23068.75 Million by 2035
Growth Rate	CAGR of 9.91% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : MECHANICAL HEART VALVE and Production Growth Rate 2011-2020 TISSUE HEART VALVE and Production Growth Rate 2011-2020 TRANSCATHETER HEART VALVE and Production Growth Rate 2011-2020 By Application : Cardiovascular Therapeutics and Key Clients (Buyers) List
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample